Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Donaldson Co Inc’s (DCI) Margins & Aftermarket Momentum Are Rising—But Can It Keep Beating Tariff Risk With Price Hikes?
Donaldson delivered a solid Q3 FY25 print that highlights resilient earnings power and disciplined execution amid macro headwinds, with adjusted EPS up 8% YoY to $0.99 on 1% sales growth to $940M and operating margin expanding 80bps to 15.8%. Strength in Mobile Solutions aftermarket (+3% YoY) and Industrial Solutions (+5% YoY) offset softness in Off-Road and On-Road OEMs, while Aerospace & Defense set new records with 27% growth and raised full-year guidance. Life Sciences remained mixed, posting modest growth but recording a $62M impairment tied to slower-than-expected bioprocessing ramp—a reset we view as realistic but raising execution risk. Management maintained FY25 guidance for 1–3% sales growth and record operating margins (15.6–16%), emphasizing the durability of its highly recurring aftermarket model and global manufacturing footprint, with 75% region-to-region sourcing and 85% USMCA coverage effectively shielding it from escalating tariff risk (~$35M exposure). Capex was trimmed to $75–$90M amid timing delays, while shareholder returns were robust with 3.5–4% buyback target and an 11% dividend hike. With shares near our revised FVE of $71, we see current valuation as fair given no structural changes to growth trajectory; can Donaldson continue to outmaneuver tariff pressures and sustain its margin expansion through pricing and supply chain agility?
